4Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas [J]. Endocrine Pathology, 2004, 15(4):319-327.
5Santarpia L, El-Naggar AK, Cote GJ, et al. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2008, 93(1):278-284.
6Boltze C, Roessner A, Landt O, et al. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma[J]. Int J Oncol, 2002, 21(5):1151-1154.
7Takano T, Ito Y. Hirokawa M, et al. BRAF V6OOE mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas [J]. Br J Cancer, 2007, 96 (10):1549-1553.
8Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer [J]. Clin Cancer Res, 2007, 13(4): 1161-1170.
9Liu D, Xing M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways [J]. Thyroid, 2008, 18(8):853-864.
10Nakashima M, Takamura N, Namba H, et al. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy [J]. Human Pathology, 2007, 38(4):621-628.
二级参考文献38
1武忠弼 杨光华主编.中华外科病理学[M].北京：人民卫生出版社,2002.646.
2Goutsouliak V,Hay JH.Anaplastic thyroid cancer in British Columbia 1985-1999:a population-based study.Clin Oncol,2005,17:75-78.
3Giuffrida D,Gharib H.Anaplastic thyroid carcinoma:current diagnosis and treatment.Ann Oncol,2000,11:1083-1089.
4Heron DE,Karimpour S,Grigsby PW.Anaplastic thyroid carcinoma:comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups.Am J Clin Oncol,2002,25:442-446.
5Sutak J,Armstrong JS,Rusby JE.Squamous cell carcinoma arising in a tall cell papillary carcinoma of the thyroid.J Clin Pathol,2005,58:662-664.
6Xing M.BRAF mutation in thyroid cancer.Endocr Relat Cancer,2005,12:245-262.
7Bacher-Stier C,Riccabona G,Totsch M,et al.Incidence and clinical characteristics or thyroid carcinoma after iodine prophylaxis in an endemic goiter country.Thyroid,1997,7:733-741.
9Beesley MF,Mc Laren KM.Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodule[J].Histopathology,2002,41(3):236.
10Shin E,Chung WY,Yang Wl,et al.RET/PTC and CK19 expression in papmary thyroid carcinoma and its clinical pathologic oorrdation[J].J Korean Med Sci,2005,20(1):98-104.
